


Respiratory clinical trials the world over, have one name - QPS



QPS
helps you navigate

THE GLOBAL FOOTPRINT OF COPD AND ASTHMA


The global burden of respiratory diseases like bronchial asthma appears to be increasing worldwide, affecting in particular subjects living in urban areas. Evidence suggests that urbanization, with its high levels of vehicle emissions and a westernised lifestyle are linked to the rising frequency of these diseases observed in most industrialized countries.

- ❑ 300 million people of all ages worldwide have asthma.
- ❑ Globally, 250 000 people die of asthma every year.
- ❑ Chronic obstructive pulmonary disease (COPD) affects 210 million people.
- ❑ Chronic obstructive pulmonary disease was the fifth cause of death in 2002 and it is projected to be the fourth cause of mortality by 2030.

CURRENT CHALLENGES

Changing environmental conditions along with increases in smoking, air pollution and urbanization has led to an increase in the prevalence of respiratory diseases. Clinical research plays an important role in understanding risk factors, drawbacks of current therapy and to find novel therapies for respiratory diseases. However, the cost and time for conducting clinical trials for respiratory diseases is higher than other diseases due to costly and time consuming testing methods. Patients are required to be tested for a longer duration leading to an increase in the total time required for drug effectiveness than seen in other diseases.





WHY CHOOSE QPS?

Knowledge and Experience = Expertise

QPS has a long tradition in conducting trials for respiratory diseases such as asthma and COPD in all clinical trial phases. It's exhaustive quantum of work as a leading CRO for respiratory drug development has contributed to its expertise in effectively conducting clinical trials in this domain.

QPS benefits from extensive experience, having conducted over 100 Phase I - IV pulmonary and respiratory studies. This experience covers a range of indications including, but not limited to COPD, Asthma, Interstitial Lung Disease (ILD) and Smoking Cessation. Our well-trained staff work together to produce high-quality studies. QPS has a strong history of supporting clinical research for new pulmonary and respiratory medications in Asia, Europe and the United States. We have the experience to take your compound from the initial planning process, to the

collection of clinical evidence, to registration. Our experience can reduce your time-to-market and minimize your costs. QPS will plan your clinical study from start to finish, putting the right team and protocol in place to ensure your trial runs smoothly.

STUDY PARTICIPANTS

Finding the right study patients is crucial for the success of your pulmonary and respiratory trials. QPS has a worldwide database of clinical investigators to ensure high patient enrollment rates conforming to strict selection criteria. The incidence of respiratory disease is so widespread that we can recruit patients with pulmonary or respiratory conditions in a number of different countries.

EXPERIENCED INVESTIGATORS

QPS has developed close relationships with the investigators who conduct your clinical trials. These relationships are the foundation for ensuring quality studies are performed. We take pride in our ability to leverage the skills of the world's most experienced investigators for every clinical trial we conduct.

QPS FOR YOUR NEXT PULMONARY OR RESPIRATORY TRIAL

Whether you need clinical trials of small molecules, biologics, immunotherapies or other medications, QPS has the experience and resources to handle your trials and get your product to market.

Should you want to discuss your questions in more detail with one of our experts, please contact us directly at: info@qps.com

REFERENCES:

1. D'Amato G. Environmental urban factors (air pollution and allergens) and the rising trends in allergic respiratory diseases. Allergy. August 2002;57(S72):30-33.
2. http://www.who.int/gard/publications/chronic_respiratory_diseases.pdf
3. <http://www.european-lung-foundation.org/63-european-lungfoundation-elf-burden-in-europe.htm>
4. http://www.japi.org/february_2012_special_issue_copd/01_editorial_india_needs_a.pdf
5. Kuo, L, Yang, P, Kuo, S Trends in the Mortality of Chronic Obstructive Pulmonary Disease in Taiwan 1981-2002. J Formos. Med Assoc 2005;104,89-93
6. <http://www.ginasthma.org/pdf/GINABurdenReport.pdf>
7. http://www.researchandmarkets.com/reports/1958232/clinical_trial_recruitment_in_respiratory



Corporate Office

Delaware Technology Park, 3 Innovation Way, Suite 240, Newark, DE 19711

Email: info@qps.com TEL: + 1 302 369 5601 FAX: + 1 302 369 5602

2012 QPS Holdings. All Rights Reserved

www.qps.com